Product
HST-1011
Aliases
CBL-B inhibitor
2 clinical trials
4 indications
Indication
Solid TumorIndication
AdultIndication
Relapsed CancerIndication
Refractory CancerClinical trial
An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase I/II, First-in-Human Study to Assess the Safety and Efficacy of Two Doses of SX600 Administered by Lumbosacral Transforaminal Epidural Injection in Patients With Radicular Pain Secondary to Lumbar Intervertebral Disc HerniationStatus: Terminated, Estimated PCD: 2022-02-21